Table 3 Univariate and multivariate analyses for predictors of persistence with initial biologic at 12 years
From: Long-term remission and biologic persistence rates: 12-year real-world data
| Â | Univariate | Multivariate | |
|---|---|---|---|
p | OR (95% CI) | p | |
Persistence at 1 year | 0.011 | 4.28 (1.28–14.38) | 0.019 |
One-year low-disease activity | < 0.001 | 3.90 (1.05–14.53) | 0.042 |
Smoker/ex-smoker at baseline | 0.055 | 0.39 (0.14–1.10) | 0.074 |
Completed university | 0.033 | 1.84 (0.54–6.27) | 0.333 |
Etanercept at baseline | 0.020 | 1.51 (0.56–4.07) | 0.411 |
Baseline alcohol use | 0.135 | 1.37 (0.47–4.04) | 0.565 |
Infliximab at baseline | 0.156 | 0.50 (0.05–5.00) | 0.557 |
Male gender | 0.061 | 0.75 (0.24–2.38) | 0.623 |
Finished secondary school | 0.010 | 0.85 (0.26–2.78) | 0.784 |
Remission at 1 year | 0.002 | 0.87 (0.27–2.86) | 0.823 |
Baseline methotrexate use | 0.084 | 1.07 (0.40–2.89) | 0.897 |
Age > 50 years | 0.797 | 0.97 (0.32–2.90) | 0.950 |